Suggested remit: To appraise the clinical and cost effectiveness of aumolertinib within its marketing authorisation for treating epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small-cell lung cancer that has not previously been treated.
Status Awaiting development
Process STA 2018
ID number 4000

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
06 October 2021 - 27 October 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance